Identification of Potential Genomic Alterations Using Pan-Cancer Cell-Free DNA Next-Generation Sequencing in Patients With Gastric Cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Molecular cancer profiling may lead to appropriate trials for molecularly tar- geted therapies. Cell-free DNA (cfDNA) is a promising diagnostic and/or prognostic bio- marker in gastric cancer (GC). We characterized somatic genomic alterations in cfDNA of patients with GC. Methods: Medical records and cfDNA data of 81 patients diagnosed as having GC were reviewed. Forty-nine and 32 patients were tested using the Oncomine Pan-Cancer Cell- Free Assay on the Ion Torrent platform and AlphaLiquid 100 kit on the Illumina platform, respectively. Results: Tier I or II alterations were detected in 64.2% (52/81) of patients. Biomarkers for potential targeted therapy were detected in 55.6% of patients (45/81), and clinical trials are underway. ERBB2 amplification is actionable and was detected in 4.9% of patients (4/81). Among biomarkers showing potential for possible targeted therapy, TP53 mutation (38.3%, 35 variants in 31 patients, 31/81) and FGFR2 amplification (6.2%, 5/81) were detected the most. Conclusions: Next-generation sequencing of cfDNA is a promising technique for the mo- lecular profiling of GC. Evidence suggests that cfDNA analysis can provide accurate and re- liable information on somatic genomic alterations in patients with GC, potentially replacing tissue biopsy as a diagnostic and prognostic tool. Through cfDNA analysis for molecular profiling, it may be possible to translate the molecular classification into therapeutic tar- gets and predictive biomarkers, leading to personalized treatment options for patients with GC in the future.
Abstract
Background: Molecular cancer profiling may lead to appropriate trials for molecularly tar- geted therapies. Cell-free DNA (cfDNA) is a promising diagnostic and/or prognostic bio- marker in gastric cancer (GC). We characterized somatic genomic alterations in cfDNA of patients with GC. Methods: Medical records and cfDNA data of 81 patients diagnosed as having GC were reviewed. Forty-nine and 32 patients were tested using the Oncomine Pan-Cancer Cell- Free Assay on the Ion Torrent platform and AlphaLiquid 100 kit on the Illumina platform, respectively. Results: Tier I or II alterations were detected in 64.2% (52/81) of patients. Biomarkers for potential targeted therapy were detected in 55.6% of patients (45/81), and clinical trials are underway. ERBB2 amplification is actionable and was detected in 4.9% of patients (4/81). Among biomarkers showing potential for possible targeted therapy, TP53 mutation (38.3%, 35 variants in 31 patients, 31/81) and FGFR2 amplification (6.2%, 5/81) were detected the most. Conclusions: Next-generation sequencing of cfDNA is a promising technique for the mo- lecular profiling of GC. Evidence suggests that cfDNA analysis can provide accurate and re- liable information on somatic genomic alterations in patients with GC, potentially replacing tissue biopsy as a diagnostic and prognostic tool. Through cfDNA analysis for molecular profiling, it may be possible to translate the molecular classification into therapeutic tar- gets and predictive biomarkers, leading to personalized treatment options for patients with GC in the future.
참고문헌 (40)
- Sung H, "Global Cancer Statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
- Cristescu R, "Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes", Nat Med, 21, pp.449~456 (2015)
- Cancer Genome Atlas Research Network, "Comprehensive molecular characterization of gastric adenocarcinoma", Nature, 513, pp.202~209 (2014)
- Kim Y, "Profiling cancer-associated genetic alterations and molecular classification of cancer in Korean gastric cancer patients", Oncotarget, 8, pp.69888~69905 (2017)
- "SEER*Explorer: an interactive website for SEER cancer statistics" (2023)[URL]
- "5-year cancer relative survival rates by SEER summary stage" (2023)[URL]
- "National Comprehensive Cancer Network Guidelines for Gastric Cancer (Version 1.2023)" (2023)[URL]
- De Mattos-Arruda L, "How to use liquid biopsies to treat patients with cancer", ESMO Open, 6, pp.100060~ (2021)
- Martínez-Saéz O, "Frequency and spectrum of PIK3CA somatic mutations in breast cancer", Breast Cancer Res, 22, pp.45~ (2020)
- Kwapisz D. The first liquid biopsy test approved, "Is it a new era of mutation testing for non-small cell lung cancer?", Ann Transl Med, 5, pp.46~ (2017)
- Grávalos C, "Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer", Clin Transl Oncol, 13, pp.179~184 (2011)
- Lee J, "Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment : the VIKTORY umbrella trial", Cancer Discov, 9, pp.1388~1405 (2019)
- Hur JY, "High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers", Pathol Res Pract, 216, pp.152878~ (2020)
- Merz V, "A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction", gastric cancer trastuzumab resistant : the FiGhTeR trial, 2020, pp.12, 1758835920937889~
- Nakamura Y, "Biomarkertargeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers : an emerging paradigm", Nat Rev Clin Oncol, 18, pp.473~487 (2021)
- Shin S, "Clinical practice guidelines for pre-analytical procedures of plasma epidermal growth factor receptor variant testing", Ann Lab Med, 42, pp.141~149 (2022)
- Li H, "Fast and accurate short read alignment with Burrows-Wheeler transform", Bioinformatics, 25, pp.1754~1760 (2009)
- Chen S, "GeneFuse : detection and visualization of target gene fusions from DNA sequencing data", Int J Biol Sci, 14, pp.843~848 (2018)
- Gawroński AR, "Structural variation and fusion detection using targeted sequencing data from circulating cell free DNA", Nucleic Acids Res, 47, pp.e38~ (2019)
- Deveson IW, "Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology", Nat Biotechnol, 39, pp.1115~1128 (2021)
- "Analytical validation of the Oncomine Pan-Cancer Cell-Free Assay. White Paper. ThermoFisher Scientific. COL33100 0619, 2019"[URL]
- So MK, "Analytical validation of a pan-cancer panel for cell-free assay for the detection of EGFR mutations", Diagnostics(Basel), 11, pp.1022~ (2021)
- Li MM, "Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists", J Mol Diagn, 19, pp.4~23 (2017)
- Kim B, "Detection of EGFR-SEPT14 fusion in cell-free DNA of a patient with advanced gastric cancer : a case report", World J Clin Cases, 9, pp.2884~2889 (2021)
- Kim S, "Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment", Br J Cancer, 127, pp.898~907 (2022)
- Li Y, "PO-086 an efficient Ion TorrentTM next generation sequencing workflow for liquid biopsy research to assess cell-free total nucleic acid", ESMO Open, 3, pp.A260~ (2018)
- Shah M, "Evaluation of the Oncomine Pan-Cancer Cell-Free Assay for analyzing circulating tumor DNA in the cerebrospinal fluid in patients with central nervous system malignancies", J Mol Diagn, 23, pp.171~180 (2021)
- Samorodnitsky E, "Evaluation of hybridization capture versus amplicon-based methods for whole-exome sequencing", Hum Mutat, 36, pp.903~914 (2015)
- He Y, "Targeting PI3K", Akt signal transduction for cancer therapy, 2021, pp.6, 425~
- Levantini E, "EGFR signaling pathway as therapeutic target in human cancers", Semin Cancer Biol, 85, pp.253~275 (2022)
- Degirmenci U, "Targeting aberrant RAS", RAF, ERK signaling for cancer therapy, pp.Cells, 2020[DOI]
- Min A, "Cyclin E overexpression confers resistance to the CDK4", 6 specific inhibitor palbociclib in gastric cancer cells, 2018, pp.430, 123~132
- Pang W, "Cyclin E : a potential treatment target to reverse cancer chemoresistance by regulating the cell cycle", Am J Transl Res, 12, pp.5170~5187 (2020)
- Gu Y, "Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy", Cancer Immunol Immunother, 72, pp.1199~1208 (2023)
- Qadir J, "Implication of ARID1A undercurrents and PDL1, TP53 overexpression in advanced gastric cancer", Pathol Oncol Res, 27, pp.1609826~ (2021)
- Fang DC, "Mutation analysis of APC gene in gastric cancer with microsatellite instability", World J Gastroenterol, 8, pp.787~791 (2002)
- Lee JH, "Seroprevalence of Helicobacter pylori in Korea : a multicenter, nationwide study conducted in 2015 and 2016", Helicobacter, 23, pp.e12463~ (2018)
- Rahman R, "Characteristics of gastric cancer in Asia", World J Gastroenterol, 20, pp.4483~4490 (2014)
- Kim HS, "Pathologic and prognostic impacts of FGFR2amplification in gastric cancer : a meta-analysis and systemic review", J Cancer, 10, pp.2560~2567 (2019)
- Zheng S, "Complete remission in leptomeningeal metastasis of NSCLC with rare EGFR-SEPT14 fusion treated with osimertinib combined with intrathecal chemotherapy with pemetrexed", Anticancer Drugs, 33, pp.e795~e798 (2022)